Effect of Baseline Characteristics on the Efficacy and Safety of Once-Daily Darunavir/ Ritonavir in HIV-1–Infected, Treatment-Naïve ARTEMIS Patients at Week 96
暂无分享,去创建一个
A. Lazzarin | J. Flamm | T. van de Casteele | L. Lavreys | N. Sosa | P. Domingo | D. Kilby | J. Ballesteros | R. Demasi | S. Spinosa‐Guzman | J. Fourie | A. Rodríguez-French